ArticleFrontiers in pharmacology2022
Calycosin attenuates renal ischemia/reperfusion injury by suppressing NF-κB mediated inflammation
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Calycosin targets the MAPK-EGR1 signaling axis to inhibit enterovirus 71 replication in cells and human colonic organoids.Virulence · 2026Article
- Calycosin Attenuates LPS-Induced Cardiomyocyte Injury Through Regulation of the PPARγ/NF-κB Signaling Pathway.International journal of molecular sciences · 2026Article
- Cerebral venous outflow disturbance exacerbates ischemic stroke via an endothelium-initiated inflammatory cascade: an integrated single-cell transcriptomic analysis.Fluids and barriers of the CNS · 2026Article
- Therapeutic effect of Yupingfeng powder and its bioactive metabolites on renal diseases.Frontiers in pharmacology · 2026Review
- Ursodeoxycholic acid alleviates high-fat diet-induced liver injury by modulating gut microbiota-mediated bile acid metabolism: an integrated microbiota-metabolomics analysis.Frontiers in nutrition · 2026Article
- Tubule-derived CCN1 drives renal repair via αCell death & disease · 2025Article
- Study on the mechanism ofAnnals of medicine · 2025Article
- Emerging Role of Calycosin in Inflammatory Diseases: Molecular Mechanisms and Potential Therapeutic Applications.Biomolecules · 2025Review
- Multi-Target Modulation of Polyphenols in Diabetic Kidney Disease Therapeutics: A Comprehensive Review.Food science & nutrition · 2025Review
- Calycosin and kidney health: a molecular perspective on its protective mechanisms.Pharmacological reports : PR · 2025Review
- Calycosin ameliorates albuminuria in nephrotic syndrome by targeting Notch1/Snail pathway.BMC nephrology · 2025Article
- Observational
- Baoshentongluo Formula relieves podocyte injury in diabetic kidney disease through regulating mitophagy via PINK1/Parkin signaling pathway.Frontiers in endocrinology · 2025Article
- METTL3, m6A modification, and EGR1: interplay affecting myocardial I/R injury outcomes.Cell biology and toxicology · 2024Article
- Counteracting Alzheimer's diseaseActa pharmaceutica Sinica. B · 2024Article
- Calycosin inhibited MIF-mediated inflammatory chemotaxis of macrophages to ameliorate ischemia reperfusion-induced acute kidney injury.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- [High STING expression exacerbates renal ischemia-reperfusion injury in mice by regulating the TLR4/NF-κB/NLRP3 pathway and promoting inflammation and apoptosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Crosstalk among proximal tubular cells, macrophages, and fibroblasts in acute kidney injury: single-cell profiling from the perspective of ferroptosis.Human cell · 2024Article
- FGF21 Inhibits Hypoxia/Reoxygenation-induced Renal Tubular Epithelial Cell Injury by Regulating the PPARγ/NF-κB Signaling Pathway.Cell biochemistry and biophysics · 2024Article
- Proteomic analysis of mitochondria associated membranes in renal ischemic reperfusion injury.Journal of translational medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal ischemia reperfusion injury (IRI) is a leading and common cause of acute kidney injury (AKI), and inflammation is a critical factor in ischemic AKI progression. Calycosin (CAL), a major active component of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.